(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma.
The AIM-traded firm said the single-arm, multi-centre, open-label study enrolled 64 patients and will...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE